Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.

@article{Liang2011SafetyOI,
  title={Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China.},
  author={X. Liang and L. Li and Dawei Liu and Ke-li Li and W. Wu and B. Zhu and Hua-Qing Wang and H. Luo and Ling-sheng Cao and Jing-shan Zheng and Da-peng Yin and L. Cao and Bing-bing Wu and Hongze Bao and Disha Xu and W. Yang and Y. Wang},
  journal={The New England journal of medicine},
  year={2011},
  volume={364 7},
  pages={
          638-47
        }
}
BACKGROUND On September 21, 2009, China began administering vaccines, obtained from 10 different manufacturers, against 2009 pandemic influenza A (H1N1) virus infection in priority populations. [...] Key Method Physicians or vaccination providers were required to report the numbers of vaccinees and all adverse events to their local Center for Disease Control and Prevention (CDC), which then reported the data to the Chinese CDC through the online National Immunization Information System's National Adverse Event…Expand
Clinical Assessment of Serious Adverse Events in Children Receiving 2009 H1N1 Vaccination
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 21 REFERENCES
A novel influenza A (H1N1) vaccine in various age groups.
Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine.
Response to a monovalent 2009 influenza A (H1N1) vaccine.
...
1
2
3
...